CONFERENCE SERIES: Technology & Tools for Life Sciences
Recorded at: PEGS: The Protein Engineering Summit
Digital Course: Alternate Display Technologies
Alternate Display Technologies Digital Course
April 29, 2012
About this Product:
Phage and yeast display have become the industry standard for those looking to isolate high affinity protein ligands against nearly any receptor through directed evolution. But what happens when phage and yeast display fall short? This digital course will cover the development of new display systems to address shortcomings of phage and yeast display, constructing libraries and assessing library quality, and screening and selection methods for generation of new affinity proteins as well as for epitope mapping purposes.
About this Product:
Over 84 Minutes
Site License: $1380
Gram-Positive Bacterial Display of Peptide and Protein Libraries
John Löfblom, Ph.D., Assistant Professor, Molecular Biotechnology, AlbaNova University Center, Royal Institute of Technology (KTH)
Biography: John Löfblom currently holds a position as Assistant Professor in combinatorial protein engineering at the School of Biotechnology at the Royal Institute of Technology (KTH) in Stockholm, Sweden. He received his Master of Science in Chemical Engineering in 2002 and a Ph.D. in Molecular Biotechnology in 2008 (KTH). In 2008, he received a grant from VINNOVA for an industry postdoc, which he conducted at the company Affibody AB (Stockholm, Sweden). The scientific profile involves combinatorial protein engineering and characterization of affinity proteins with a focus on method development. John is co-developer of a novel staphylococcal surface display system for directed evolution purposes. The current focus of his research involves investigation of small protein scaffolds for therapy applications and development of selection strategies as well as protein characterization assays (e.g. epitope mapping and cross reactivity studies) using primarily cell display.
Screen with a View: Peptide Engineering with E. coli Display
Patrick S. Daugherty, Ph.D., Professor and Vice Chair, Department of Chemical Engineering, & Biomolecular Science & Engineering Program, University of California, Santa Barbara
Biography: Patrick Daugherty is Professor and Vice Chair of Chemical Engineering, and Biomolecular Science and Engineering at the University of California, Santa Barbara. He received his B.S. in Chemical Engineering from The University of Minnesota in 1993, and his Ph.D. from the University of Texas at Austin in 1999. He was a Senior Research Fellow at the Fred Hutchinson Cancer Research Center in Seattle during 1999-2001, before joining the Chemical Engineering faculty at UCSB in 2001. He is the recipient of a National Sciences Foundation Career Award (2005), Camille Dreyfus Teacher Scholar Award (2006), and an ACS Young Investigator Award from the Division of Biochemical Technology (2007). Daugherty founded the therapeutic biotechnology company CytomX Therapeutics, Inc. (South San Francisco, CA) and co-founded medical device company Cynvenio Biosystems Inc. (Westlake Village, CA). In 2011, Dr. Daugherty was elected to the American Institute of Medical and Biological Engineering (AIMBE). Professor Daugherty’s research is focused on elucidating the features of specific protein-peptide interactions, and engineering their binding and catalytic functions. Daugherty’s group has developed bacterial display technologies that enable rapid affinity ligand and protease substrate engineering, as well as intracellular protein interaction and enzyme screening approaches using fluorescent protein biosensors. This successful work has led his laboratory to investigate applications of bacterial display technology to the development proteins and peptides for therapeutic and diagnostics use.
About the Conference:
Cambridge Healthtech Institute is proud to present the Eighth Annual PEGS, protein engineering summit. Topics span from early stage discovery of new methods for protein expression and antibody engineering, to improved analytical techniques, and clinical results in the most promising areas of biotechnology. This event captures the tremendous momentum and investment in biologics, and offers a comprehensive look at recombinant proteins and antibodies and novel constructs.